Expression level of beta-catenin is associated with prognosis of esophageal carcinoma

Lv, Jian; Cao, Xiufeng; Wang, Heming; Li, Yi-Sheng; Zhu, Bin; Xiao, Jian; Wang, Dan

doi:10.3748/wjg.v13.i18.2622

Cited by 10 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So, it is important to explore what role Wnt=b-catenin plays in ESCC. A previous study had found that b-catenin mRNA expression was obviously abnormal in early ESCC and overexpression was implicated in poor prognosis of ESCC patients ( Ji et al, 2007). Without a doubt, the present results proved it once again.…”

Section: Discussionsupporting

confidence: 81%

Association of Wnt1/β-Catenin with Clinical Pathological Characteristics and Prognosis of Esophageal Squamous Cell Carcinoma

Cao¹,

Ji²,

Zhu³

et al. 2010

Genetic Testing and Molecular Biomarkers

Self Cite

View full text Add to dashboard Cite

The aim of this study was to investigate the correlation between Wnt1=b-catenin expression and the clinicopathologic features and prognosis of patients with esophageal squamous cell carcinoma (ESCC). The mRNA and protein expression levels of Wnt1=b-catenin genes in 70 ESCC and 15 adjacent noncancerous paraffin-embedded samples were determined by real-time quantitative polymerase chain reaction and immunohistochemical staining. The mRNA expression level of Wnt1=b-catenin in ESCC was significantly higher than that in the adjacent noncancerous tissues (1.9934 AE 1.9888 vs. 0.8863 AE 0.665, p ¼ 0.0184; 0.2854 AE 0.1298 vs. 0.0128 AE 0.0158, p ¼ 0.0000, respectively), and the overexpression of Wnt1=b-catenin mRNA was aggressively associated with lymph node metastasis and advanced pathological stage ( p < 0.0001). The protein expression level of Wnt1= b-catenin was also significantly higher than that in the adjacent noncancerous tissues (0.3830 AE 0.0947 vs. 0.2721 AE 0.1474, p ¼ 0.0002; 0.2835 AE 0.0844 vs. 0.2352 AE 0.0670, p ¼ 0.0210, respectively); however, the overexpression was not associated with clinicopathologic characteristics. Meanwhile, the protein expression level of Wnt1 had no relevance with that of b-catenin. The overexpression of Wnt1=b-catenin might be an important molecular marker to predict the clinicopathologic stage and prognosis of ESCC, and the level of Wnt1=b-catenin mRNA was conversely correlated with lymph node metastasis and advanced pathological stage. The overexpression of Wnt1=b-catenin mRNA should also predict poor prognosis of ESCC; however, it might not be an independent prognostic factor.

show abstract

Section: Discussionsupporting

confidence: 81%

Association of Wnt1/β-Catenin with Clinical Pathological Characteristics and Prognosis of Esophageal Squamous Cell Carcinoma

Cao¹,

Ji²,

Zhu³

et al. 2010

Genetic Testing and Molecular Biomarkers

Self Cite

View full text Add to dashboard Cite

show abstract

“…The Wnt signaling pathway may be activated through the accumulation and/or altered localization of β-catenin. Thereafter, β-catenin forms a complex with the TCF/LEF family of transcription factors, resulting in the activation of growth-controlling genes ( 14 – 17 ). The role of β-catenin in human carcinomas has been extensively studied ( 15 – 17 ).…”

Section: Discussionmentioning

confidence: 99%

Expression and prognostic value of SFRP1 and β-catenin in patients with glioblastoma

Chang

Lei

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

The roles of secreted frizzled-related protein-1 (SFRP1) and β-catenin in human cancer have been widely studied, and it has recently been demonstrated that these proteins are associated with numerous human carcinomas. However, their clinical significance in glioblastoma multiforme (GBM) has not been examined. The current study aimed to analyze the correlation between the expression of SFRP1 and β-catenin, and clinicopathological characteristics in GBM patients. The expression of SFRP1 and β-catenin was assessed by immunohistochemistry in 113 samples of GBM and 40 normal brain tissues. Compared with normal brain tissues, GBM tissues exhibited significantly lower expression of SFRP1, and higher expression of β-catenin (both P<0.05). A Kaplan-Meier analysis revealed that patients with positive SFRP1 expression had a significantly longer overall survival (OS) time relative to those with negative SFRP1 expression (P<0.000), and that patients with positive β-catenin expression had a shorter OS time than those with negative β-catenin expression (P<0.000). A multivariate Cox regression analysis indicated that adjuvant treatment, SFRP1 expression and β-catenin expression were independent prognostic factors for OS (P<0.000, P=0.008 and P=0.001, respectively) in patients with GBM. The current data suggest that expression of SFRP1 and β-catenin may be considered significant prognostic indicators for patients with GBM.

show abstract

“…Several reports indicate that esophageal squamous cell carcinoma (ESCC) has abnormal nuclear accumulation of β-catenin accompanied with increased cyclin D1 expression 135 . β-catenin mRNA expression has appeared a new prognostic marker for ESCC 136 . Overexpression of β-catenin and its target proteins is commonly observed in human Eca109 tumor xenografts.…”

Section: Targeting Cancer Cells By Regulating Multiple Signaling Pmentioning

confidence: 99%

Targeting Apoptosis and Multiple Signaling Pathways with Icariside II in Cancer Cells

Khan¹,

Maryam²,

Qazi³

et al. 2015

Int. J. Biol. Sci.

123

119

View full text Add to dashboard Cite

Cancer is the second leading cause of deaths worldwide. Despite concerted efforts to improve the current therapies, the prognosis of cancer remains dismal. Highly selective or specific blocking of only one of the signaling pathways has been associated with limited or sporadic responses. Using targeted agents to inhibit multiple signaling pathways has emerged as a new paradigm for anticancer treatment. Icariside II, a flavonol glycoside, is one of the major components of Traditional Chinese Medicine Herba epimedii and possesses multiple biological and pharmacological properties including anti-inflammatory, anti-osteoporosis, anti-oxidant, anti-aging, and anticancer activities. Recently, the anticancer activity of Icariside II has been extensively investigated. Here, in this review, our aim is to give our perspective on the current status of Icariside II, and discuss its natural sources, anticancer activity, molecular targets and the mechanisms of action with specific emphasis on apoptosis pathways which may help the further design and conduct of preclinical and clinical trials.Icariside II has been found to induce apoptosis in various human cancer cell lines of different origin by targeting multiple signaling pathways including STAT3, PI3K/AKT, MAPK/ERK, COX-2/PGE2 and β-Catenin which are frequently deregulated in cancers, suggesting that this collective activity rather than just a single effect may play an important role in developing Icariside II into a potential lead compound for anticancer therapy. This review suggests that Icariside II provides a novel opportunity for treatment of cancers, but additional investigations and clinical trials are still required to fully understand the mechanism of therapeutic effects to further validate it in anti-tumor therapy.

show abstract

Expression level of beta-catenin is associated with prognosis of esophageal carcinoma

Cited by 10 publications

References 21 publications

Association of Wnt1/β-Catenin with Clinical Pathological Characteristics and Prognosis of Esophageal Squamous Cell Carcinoma

Association of Wnt1/β-Catenin with Clinical Pathological Characteristics and Prognosis of Esophageal Squamous Cell Carcinoma

Expression and prognostic value of SFRP1 and β-catenin in patients with glioblastoma

Targeting Apoptosis and Multiple Signaling Pathways with Icariside II in Cancer Cells

Contact Info

Product

Resources

About